May 27th 2024
A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.
Dapagliflozin Safe and Effective in Stage 4 Chronic Kidney Disease, DAPA-CKD Analysis Finds
July 20th 2021A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.
FDA Panel Votes Against Roxadustat, Cites Risk of Thrombotic Events
July 16th 2021The subject of a July 15 meeting, the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 13-1 and 12-2 against recommending approval of roxadustat for treatment of anemia in adult patients with chronic kidney disease not on dialysis and on dialysis, respectively.
Finerenone (KERENDIA) Approved for Chronic Kidney Disease Associated with Type 2 Diabetes
July 9th 2021With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for use in adults with chronic kidney disease associated with type 2 diabetes.
DISCOVER Details Gradual Uptake, Need for Improvement in Prescribing of SGLT2 Inhibitors, GLP-1 RAs
July 2nd 2021Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.
ADA 2021: Sotagliflozin Impact in Patients with Type 2 Diabetes Highlighted in Special Session
June 29th 2021While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.
AMPLITUDE-O: Efpeglenatide Shows Promise for Reducing CV, Kidney Events in Patients with Diabetes
June 28th 2021Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.
Finerenone Provides Consistent Benefit, Irrespective of Background GLP-1 RA Use
June 26th 2021A FIDELIO-DKD analysis presented at ADA 2021 suggests the renal and cardiovascular benefits of finerenone were consistent, irrespective of background GLP-1 RA use and indicate the presence of both was associated with even greater reductions in albuminuria.
Dapagliflozin Cuts Risk of Diabetes in Patients with Chronic Kidney Disease
June 25th 2021A prespecified analysis of DAPA-CKD presented at ADA 2021 suggests use of dapagliflozin reduced the incidence of type 2 diabetes by nearly 40% among patients with chronic kidney disease but without diabetes within the phase 3 trial.
Finerenone and SGLT2 Inhibitors Could Have Additive Effect on Kidney Protection
June 25th 2021Data from an analysis of FIDELIO-DKD suggests the renoprotective benefits of finerenone were consistent irrespective of SGLT2 inhibitor use and those using an SGLT2 inhibitor with finerenone resulted in greater UACR reductions.
Study Provides Overview of ESKD, Cardiovascular Risk in Adults with Nephrotic Syndrome
June 20th 2021Comparing data from patients with primary nephrotic syndrome to matched controls in a 1:100 ratio, investigators found these patients were at a 19-fold greater risk of end-stage kidney disease and a 3-fold greater risk of acute coronary syndrome events.